In the previous post on psilocybin, we explored the extraordinary territory of full psychedelic doses — the mystical experiences, the clinical trials for depression and addiction, the philosophical implications of a molecule that may be opening a window into consciousness as it actually is rather than as the brain’s reducing valve ordinarily presents it. But there is a quieter, more everyday practice emerging from the psilocybin renaissance that is drawing its own growing body of research, its own community of practitioners, and its own set of remarkable reported effects.
Microdosing. The practice of taking psilocybin in doses so small they produce no perceptible psychedelic effects — no hallucinations, no ego dissolution, no alteration of ordinary functioning — while potentially producing subtle but significant improvements in mood, focus, creativity, emotional resilience, and general wellbeing. It is, in effect, an attempt to access the neurological benefits of psilocybin at the sub-perceptual level — below the threshold of experience but above the threshold of biological effect.
The science is early. The anecdotal evidence is substantial. And the questions it raises about consciousness, neuroplasticity, and the biology of wellbeing are genuinely fascinating.
What Microdosing Is
A standard full psychedelic dose of dried psilocybin mushrooms is typically 2-5 grams, producing profound alterations in perception, cognition, and sense of self lasting 4-6 hours. A microdose is typically 0.05-0.3 grams — approximately one-tenth to one-twentieth of a full dose. At this level, the dose is designed to be sub-perceptual: the person taking it should be able to go about their normal day without anyone around them noticing any change, and without experiencing any of the perceptual or cognitive alterations associated with higher doses.
The practice was popularized in the broader public consciousness largely through journalist Michael Pollan’s 2018 book How to Change Your Mind and through James Fadiman — a psychedelic researcher who has been collecting microdosing reports for over a decade and whose work provided the first systematic documentation of what people experience when they microdose. Fadiman’s research, published in The Psychedelic Explorer’s Guide, described a consistent pattern of reported benefits that has since been investigated more rigorously in formal research settings.
Common Microdosing Protocols
Several dosing protocols have emerged from the microdosing community, each with different rationales and different reported effects.
The Fadiman Protocol — named for James Fadiman — involves dosing every third day: one day on, two days off. The rationale is that psilocybin and its active metabolite psilocin have a short half-life, but the neurological effects may persist longer. The two off days allow for full clearance and prevent the development of tolerance while maintaining consistent neurological benefit. This is the most widely used protocol and the one most studied in formal research.
The Stamets Protocol — developed by mycologist Paul Stamets — involves four days on, three days off, and combines psilocybin mushrooms with lion’s mane mushroom (which promotes nerve growth factor production and supports neurogenesis) and niacin (which may help distribute the other compounds throughout the nervous system). Stamets argues this combination produces synergistic neuroplasticity effects beyond what psilocybin alone achieves. The protocol is widely used but has been studied less rigorously than the Fadiman protocol.
Intuitive or spontaneous dosing — some practitioners dose as needed, without a fixed schedule, using subjective experience and awareness to guide timing. This approach is harder to study but reflects the reality that many microdosers adapt their practice to their own rhythms and needs.
What the Research Shows
Formal research on microdosing is still in relatively early stages, hampered by the same regulatory challenges that slowed full-dose psychedelic research for decades. Most available evidence comes from observational studies, self-report surveys, and a small number of controlled trials. The picture that emerges is nuanced — with consistent signals in some domains and more mixed findings in others.
Mood and wellbeing. The most consistent finding across multiple observational studies is improved mood and reduced symptoms of depression and anxiety in people who microdose. A large observational study published in Scientific Reports in 2021 tracking over 1,100 microdosers found significant improvements in mood, focus, creativity, and wellbeing compared to non-microdosers over a 30-day period. Depression and anxiety symptoms decreased. Neuroticism decreased. A sense of psychological flexibility and openness increased.
Focus and cognitive performance. Many microdosers report improved concentration, mental clarity, and the ability to engage deeply with complex tasks. Some also report enhanced pattern recognition and creative problem-solving. Controlled laboratory studies have found mixed results on objective cognitive performance measures — some showing improvements in fluid intelligence and divergent thinking, others finding minimal effects compared to placebo. The gap between subjective experience and objective laboratory measures may reflect the subtlety of the effects, the variability in individual response, or the limitations of laboratory tasks in capturing real-world cognitive benefits.
The expectancy question. A significant complication in microdosing research is the expectancy effect — the well-documented tendency for people to experience what they expect to experience when they know they are taking a substance with certain reported effects. Several placebo-controlled studies have found that some of the benefits reported by microdosers are partially attributable to expectancy rather than pharmacological effect. This does not necessarily mean microdosing doesn’t work — placebo effects are real biological phenomena, and the expectancy that one has taken a beneficial substance produces genuine neurochemical changes — but it does mean that the specific contribution of psilocybin over and above expectancy is not yet fully characterized.
Neuroplasticity at sub-perceptual doses. Research on neuroplasticity suggests that psilocybin promotes dendritic spine growth and structural synaptic plasticity even at doses below those producing perceptible effects. If this effect persists at microdose levels — which early research suggests it may — it could explain the reported improvements in cognitive flexibility and mood through a mechanism that is genuinely pharmacological rather than expectancy-driven. The brain literally becomes more structurally plastic, more capable of forming new patterns, even at doses that produce no conscious experience of anything unusual.
What People Report: The Lived Experience
Beyond the formal research, the qualitative picture from thousands of microdosers’ self-reports paints a consistent portrait of what the practice actually feels like from the inside. The reports are not uniform — individual variation is significant — but certain themes emerge with enough regularity to be meaningful.
A slight brightening of the day. Many microdosers describe a subtle but distinct quality of increased aliveness, color, and engagement with ordinary experience. Not euphoria — nothing dramatic — but a kind of enhanced presence, as if the day is slightly more vivid and worth paying attention to. Small things become more interesting. Ordinary tasks become less effortful. The habitual negativity bias of the default mind loses some of its grip.
Emotional openness and reduced reactivity. Many people report finding themselves less reactive to emotional triggers — more able to feel feelings without being controlled by them, more able to pause between stimulus and response. This increased emotional spaciousness is one of the most consistently reported and most therapeutically significant effects, and it mirrors what full doses produce at a much more dramatic level: the disruption of rigid, automatic emotional patterns and the creation of space for more conscious response.
Enhanced connection. A common report is increased warmth and connection in relationships — greater empathy, more genuine interest in other people, more ease in social situations. Some people report that microdosing helps them be more present with their children, more patient with partners, more open with friends. The quality of attention they bring to their closest relationships improves.
Increased creative flow. Artists, writers, musicians, and other creative practitioners report that microdosing reduces the friction between intention and expression — the inner critic quiets, the internal censor loosens, and the creative process flows more freely. Silicon Valley’s well-documented interest in microdosing is largely driven by reports of enhanced creative problem-solving and the ability to hold multiple perspectives simultaneously.
The challenges. Not all reports are positive. Some microdosers experience anxiety, emotional intensity, or what is sometimes called “waving” — a subtle undulation of mood and energy across the day that can be uncomfortable. Some find that microdosing surfaces difficult emotions that they were not ready to process. Some experience perceptual sensitivity — lights seeming brighter, sounds more intense — that is uncomfortable in some settings. These challenges are generally manageable through dose adjustment, protocol modification, or — importantly — professional therapeutic support, which most practitioners recommend as an adjunct to any consistent psychedelic practice.
The Broader Context: Integration and Intention
The most consistent finding across both formal research and practitioner experience is that microdosing works best when embedded in a broader practice of intentional living — when it is accompanied by journaling, meditation, therapy, time in nature, quality sleep, exercise, and deliberate attention to the inner life. Psilocybin — at any dose — appears to function as an amplifier: it amplifies what is already present in the person’s life and inner state, whether positive or negative. Used with intention, in a supportive context, with adequate preparation and reflection, the amplification tends to be therapeutic. Used without intention, in a chaotic context, without reflection or integration, the results are less predictable.
This is consistent with the ancient wisdom traditions that worked with psilocybin mushrooms ceremonially rather than casually — that understood these substances as tools requiring respect, preparation, and skilled guidance rather than simple medications to be taken without context. The mushroom does not do the work. It creates conditions in which the work becomes possible. What you bring to those conditions — your intention, your openness, your willingness to examine what emerges — determines what you take away.
The Legal Landscape
Psilocybin remains a Schedule I controlled substance at the federal level in the United States and is illegal in most countries, meaning that microdosing psilocybin mushrooms is currently illegal in most jurisdictions. Oregon and Colorado have created legal frameworks for supervised psilocybin services at full doses, but personal possession and use remains a legal gray area or outright illegal in most places. The regulatory landscape is evolving rapidly as the clinical evidence accumulates, and several jurisdictions are actively reviewing their policies. Anyone considering microdosing should be fully informed of the legal context in their area.
The science is pointing somewhere extraordinary. The ancient traditions knew something we are only beginning to formally characterize. And the question of how to integrate these findings — the neuroscience, the clinical evidence, the experiential reports, the ancient wisdom — into a coherent understanding of consciousness, healing, and human potential is one of the most interesting questions of our time.
Positive thoughts create positive outcomes. And the emerging science of microdosing suggests that subtle, consistent support for neuroplasticity and emotional openness may be one of the most powerful foundations for positive thinking available — the brain literally becoming more capable of new thoughts, new patterns, and new ways of being in the world.
Explore the Mushroom Collection
High Phase honors the extraordinary world of fungi and the expanding conversation about consciousness, healing, and human potential.